Proposed Data Collections Submitted for Public Comment and Recommendations, 4148-4149 [2013-00988]
Download as PDF
<![CDATA[
4148
Federal Register / Vol. 78, No. 13 / Friday, January 18, 2013 / Notices
Name
CAS
1. Trichloroethylene (UPDATE) ..
2. Tetrachloroethylene (UPDATE).
3. Hydrogen sulfide/Carbonyl
sulfide (UPDATE).
4. Glutaraldehyde (NEW) ...........
5. Parathion (NEW) ....................
79–01–6
127–18–4
7783–06–4
463–58–1
111–30–8
56–38–2
Clifton Road NE., Mail Stop F–57,
Atlanta, GA 30333, telephone 770–488–
3313.
Dated: January 11, 2013.
Ken Rose,
Director, Office of Policy Planning and
Evaluation, National Center for
Environmental Health.
[FR Doc. 2013–00991 Filed 1–17–13; 8:45 am]
mstockstill on DSK4VPTVN1PROD with
SUPPLEMENTARY INFORMATION:
The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) (42
U.S.C. 9601 et seq.) amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) (42
U.S.C. 9601 et seq.) by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) with regard to hazardous
substances that are most commonly
found at facilities on the CERCLA
National Priorities List (NPL). Among
these statutory requirements is a
mandate for the Administrator of
ATSDR to prepare toxicological profiles
for each substance included on the
Priority List of Hazardous Substances
(www.atsdr.cdc.gov/SPL). This list
names 275 hazardous substances that
pose the most significant potential
threat to human health as determined by
ATSDR and EPA. The availability of the
revised list of the 275 priority
substances was announced in the
Federal Register on November 3, 2011
(76 FR 68193). For prior versions of the
list of substances, see Federal Register
notices dated April 17, 1987 (52 FR
12866); October 20, 1988 (53 FR 41280);
October 26, 1989 (54 FR 43619); October
17, 1990 (55 FR 42067); October 17,
1991 (56 FR 52166); October 28, 1992
(57 FR 48801); February 28, 1994 (59 FR
9486); April 29, 1996 (61 FR 18744;
November 17, 1997 (62 FR 61332);
October 21, 1999 (64 FR 56792); October
25, 2001 (66 FR 54014); November 7,
2003 (68 FR 63098); December 7, 2005
(70FR 70284): and March 6, 2008 (73 FR
12178).
Notice of the availability of drafts of
these five toxicological profiles for
public review and comment will be
published in the Federal Register on or
about October 17, 2013, with notice of
a 90-day public comment period for
each profile, starting from the actual
release date. Following the close of the
comment period, chemical-specific
comments will be addressed, and,
where appropriate, changes will be
incorporated into each profile.
FOR FURTHER INFORMATION CONTACT:
Commander Jessilynn B. Taylor,
Division of Toxicology and Human
Health Sciences, Agency for Toxic
Substances and Disease Registry, 1600
VerDate Mar<15>2010
16:52 Jan 17, 2013
Jkt 229001
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–13–0600]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 or send
comments to Ron Otten, 1600 Clifton
Road, MS–D74, Atlanta, GA 30333 or
send an email to omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
CDC Model Performance Evaluation
Program (MPEP) for Mycobacterium
tuberculosis and Nontuberculous
Mycobacteria Drug Susceptibility
Testing OMB #0920–0600 (exp. 5/31/
2013),—Revision—National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Background and Brief Description
As part of the continuing effort to
support domestic public health
objectives for treatment of tuberculosis
(TB), prevention of multi-drug
resistance, and surveillance programs,
CDC is requesting approval from the
Office of Management and Budget to
continue data collection from
participants in the Model Performance
Evaluation Program for Mycobacterium
tuberculosis and Non-tuberculous
Mycobacterium Drug Susceptibility
Testing. This revision request includes
(a) Changing the title of the data
collection to ‘‘CDC Model Performance
Evaluation (MPEP) for Mycobacterium
tuberculosis Drug Susceptibility
Testing’’ to reflect that nontuberculous
mycobacteria are no longer included in
the test package; (b) replacement of
Laboratory Enrollment Form with a
Participant Biosafety Compliance Letter
of Agreement; (c) revision of the Preshipment Email; (d) addition of
Instructions to Participants Letter; (e)
revision of the MPEP M. tuberculosis
Results Worksheet; (f) entering survey
results online using a modified data
collection instrument; (g) modification
of Reminder Email; (h) modification of
Reminder Telephone Script; and (i)
modification of the Aggregate Report
Letter.
While the overall number of cases of
TB in the U.S. has decreased, rates still
remain high among foreign-born
persons, prisoners, homeless
populations, and individuals infected
with HIV in major metropolitan areas.
To reach the goal of eliminating TB, the
Model Performance Evaluation Program
for Mycobacterium tuberculosis and
Non-tuberculous Mycobacterium Drug
Susceptibility Testing is used to monitor
and evaluate performance and practices
among national laboratories performing
M. tuberculosis susceptibility testing.
Participation in this program is one way
laboratories can ensure high-quality
laboratory testing, resulting in accurate
and reliable testing results.
By providing an evaluation program
to assess the ability of the laboratories
to test for drug resistant M. tuberculosis
strains, laboratories also have a selfassessment tool to aid in optimizing
their skills in susceptibility testing. The
information obtained from the
laboratories on susceptibility practices
and procedures is used to establish
variables related to good performance,
assessing training needs, and aid with
the development of practice standards.
Participants in this program include
domestic clinical and public health
laboratories. Data collection from
laboratory participants occurs twice per
E:\FR\FM\18JAN1.SGM
18JAN1
4149
Federal Register / Vol. 78, No. 13 / Friday, January 18, 2013 / Notices
year. The data collected in this program
will include the susceptibility test
results of primary and secondary drugs,
drug concentrations, and test methods
performed by laboratories on a set of
performance evaluation (PE) samples.
The PE samples are sent to participants
twice a year. Participants also report
demographic data such as laboratory
type and the number of tests performed
annually.
There is no cost to respondents to
participate other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondent
Domestic Laboratory
Total ....................
Number of
respondents
Form name
Total burden
hours
93
2
5/60
16
93
2
30/60
93
93
2
15/60
47
..................................................................................
........................
0
........................
156
[FR Doc. 2013–00988 Filed 1–17–13; 8:45 am]
BILLING CODE 4163–18–P
Proposed Project
Restriction on Interstate Travel of
Persons (OMB Control No. 0920–0488,
Exp. 3/31/2013)—Revision—National
Center for Emerging and Zoonotic
Infectious Diseases (NCEZID), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–13–0488]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
requests, call (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC 20503 or by fax to (202) 395–5806.
Written comments should be received
within 30 days of this notice.
The Centers for Disease Control and
Prevention is requesting OMB approval
for a revision of the information
collection, ‘‘Restriction on Interstate
Travel of Persons’’ (OMB Control No.
0920–0488).
This information collection request is
scheduled to expire on March 31, 2013.
CDC is authorized to collect this
information under 42 CFR 70.5 (Certain
communicable diseases; special
requirements). This regulation requires
that any person who is in the
communicable period for cholera,
plague, smallpox, typhus, or yellow
fever or having been exposed to any
such disease is in the incubation period
thereof, to apply for and receive a
permit from the Surgeon General or his
authorized representative in order to
travel from one State or possession to
another.
CDC is requesting changes to the
forms used within this information
collection. The changes involve splitting
the current form into two separate forms
based on the type of respondent: an ill
traveler, or the master of a vessel or
conveyance engaged in interstate travel.
CDC is also adding the option of
electronic reporting of illness.
Control of disease transmission
within the States is considered to be the
province of state and local health
authorities, with Federal assistance
being sought by those authorities on a
cooperative basis without application of
Federal regulations. The regulations in
42 Part 70 were developed to facilitate
Federal action in the event of large
outbreaks requiring a coordinated effort
involving several states, or in the event
of inadequate local control. While it is
not known whether, or to what extent
situations may arise in which these
regulations would be invoked,
contingency planning for domestic
emergency preparedness is now
commonplace. Should these situations
arise, CDC will use the reporting and
recordkeeping requirements contained
in the regulations to carry out
quarantine responsibilities as required
by law. The total number of burden
hours requested for this collection is
3,701.
There is no cost to respondents other
than their time.
Form name
Traveler ............................................
42 CFR 70.3 Application to the State of destination
for a permit.
42 CFR 70.3 Copy of material submitted by applicant and permit issued by State health authority.
42 CFR 70.3 Copy of material submitted by applicant and permit issued by State health authority.
Attending physician ..........................
State health authority .......................
16:52 Jan 17, 2013
Jkt 229001
PO 00000
Frm 00030
Fmt 4703
Number of
responses per
respondent
Number of
respondents
Type of respondent
VerDate Mar<15>2010
Average
burden per
response
(in hours)
Participant Biosafety Compliance Letter of Agreement.
MPEP Mycobacterium tuberculosis Results Worksheet.
Online Survey Instrument ........................................
Dated: January 14, 2013.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Director, Centers for
Disease Control and Prevention.
mstockstill on DSK4VPTVN1PROD with
Number of
responses per
respondent
Sfmt 4703
E:\FR\FM\18JAN1.SGM
Average
burden per
response
(in hours)
2,000
1
15/60
2,000
1
15/60
8
250
6/60
18JAN1
]]>Agencies
[Federal Register Volume 78, Number 13 (Friday, January 18, 2013)]
[Notices]
[Pages 4148-4149]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00988]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-13-0600]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570 or
send comments to Ron Otten, 1600 Clifton Road, MS-D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
CDC Model Performance Evaluation Program (MPEP) for Mycobacterium
tuberculosis and Nontuberculous Mycobacteria Drug Susceptibility
Testing OMB 0920-0600 (exp. 5/31/2013),--Revision--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
As part of the continuing effort to support domestic public health
objectives for treatment of tuberculosis (TB), prevention of multi-drug
resistance, and surveillance programs, CDC is requesting approval from
the Office of Management and Budget to continue data collection from
participants in the Model Performance Evaluation Program for
Mycobacterium tuberculosis and Non-tuberculous Mycobacterium Drug
Susceptibility Testing. This revision request includes (a) Changing the
title of the data collection to ``CDC Model Performance Evaluation
(MPEP) for Mycobacterium tuberculosis Drug Susceptibility Testing'' to
reflect that nontuberculous mycobacteria are no longer included in the
test package; (b) replacement of Laboratory Enrollment Form with a
Participant Biosafety Compliance Letter of Agreement; (c) revision of
the Pre-shipment Email; (d) addition of Instructions to Participants
Letter; (e) revision of the MPEP M. tuberculosis Results Worksheet; (f)
entering survey results online using a modified data collection
instrument; (g) modification of Reminder Email; (h) modification of
Reminder Telephone Script; and (i) modification of the Aggregate Report
Letter.
While the overall number of cases of TB in the U.S. has decreased,
rates still remain high among foreign-born persons, prisoners, homeless
populations, and individuals infected with HIV in major metropolitan
areas. To reach the goal of eliminating TB, the Model Performance
Evaluation Program for Mycobacterium tuberculosis and Non-tuberculous
Mycobacterium Drug Susceptibility Testing is used to monitor and
evaluate performance and practices among national laboratories
performing M. tuberculosis susceptibility testing. Participation in
this program is one way laboratories can ensure high-quality laboratory
testing, resulting in accurate and reliable testing results.
By providing an evaluation program to assess the ability of the
laboratories to test for drug resistant M. tuberculosis strains,
laboratories also have a self-assessment tool to aid in optimizing
their skills in susceptibility testing. The information obtained from
the laboratories on susceptibility practices and procedures is used to
establish variables related to good performance, assessing training
needs, and aid with the development of practice standards.
Participants in this program include domestic clinical and public
health laboratories. Data collection from laboratory participants
occurs twice per
[[Page 4149]]
year. The data collected in this program will include the
susceptibility test results of primary and secondary drugs, drug
concentrations, and test methods performed by laboratories on a set of
performance evaluation (PE) samples. The PE samples are sent to
participants twice a year. Participants also report demographic data
such as laboratory type and the number of tests performed annually.
There is no cost to respondents to participate other than their
time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Domestic Laboratory.......... Participant 93 2 5/60 16
Biosafety
Compliance
Letter of
Agreement.
MPEP 93 2 30/60 93
Mycobacterium
tuberculosis
Results
Worksheet.
Online Survey 93 2 15/60 47
Instrument.
---------------------------------------------------------------
Total.................... ................. .............. 0 .............. 156
----------------------------------------------------------------------------------------------------------------
Dated: January 14, 2013.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI), Office of the Associate
Director for Science (OADS), Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2013-00988 Filed 1-17-13; 8:45 am]
BILLING CODE 4163-18-P
